Agent clears toxic proteins and improves cognition in neurodegeneration models

July 16, 2017

Researchers have found cell receptors abnormally overexpressed in post-mortem brains of those with Parkinson's and Alzheimer's diseases, and that they can be inhibited in animal models to clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance.

These dual findings, presented by Georgetown University Medical Center (GUMC) researchers at the Alzheimer's Association International Conference in London, mark the first time that the receptors, discoindin domain receptors (DDRs), have been understood to play a role in Parkinson's and Alzheimer's diseases. (They are primarily known as potential targets against cancer.)

"Activation of these appear to prevent cells from cleaning out the trash - the toxic buildup of proteins, such as alpha-synuclein, tau and amyloid, common in ," says the study's senior author, neurologist Charbel Moussa, MBBS, PhD, director of Georgetown's Laboratory for Dementia and Parkinsonism, and scientific and clinical research director of the GUMC Translational Neurotherapeutics Program.

When DDRs are over-expressed, their actions become destructive. One reason may be that DDRs are protein enzymes known as tyrosine kinases that act as on and off switches of the cell self-cleaning process known as autophagy. Excess DDRs activation may switch off autophagy, resulting in build-up of toxic proteins inside and possibly breakdown of the blood-brain barrier, common in neurodegenerative diseases, he says.

DDRs inhibition with a tyrosine kinase inhibitor appears to insulate the brain via repair, which prevents harmful immune cells that circulate in the body from getting into the brain where they can indiscriminately attack and kill healthy and sick neurons, like those that have been unable to perform autophagy to "take out their trash," says Moussa.

"We studied an experimental that enters the brain and inhibits DDRs," explains Moussa, associate professor of neurology. "Inhibition of these receptors with a low dose of the agent, LCB-03-110, or reduction of DDRs expression in several models of Parkinson's and Alzheimer's , allows nerve cells to switch on autophagy to clear toxic proteins and help the brain insulate itself from circulating inflammatory . This led to cognitive improvement in our animal models."

Moussa has found other agents that target the process of autophagy. One such agent nilotinib (Tasigna by Novartis), used to treat leukemia, is being studied in patients with Parkinson's and Alzheimer's diseases.

Study collaborators include, from Moussa's lab Michaeline Hebron, MS, Monica Javidnia, and Irina Lonskaya, PhD, a postdoctoral researcher.

Georgetown has filed a patent application related to use of certain DDR inhibitors for the treatment of neurodegenerative diseases. Moussa is the named inventor of the intellectual property protected. Also, Georgetown holds an issued US patent on related technology for the use of nilotinib for the treatment of certain neurodegenerative diseases and has other pending patent applications in US and foreign jurisdictions. Moussa is also the named inventor on this related intellectual property, which the university has licensed to a company for further development and commercialization.

Explore further: More evidence in quest to repurpose cancer drugs for Alzheimer's disease

Related Stories

More evidence in quest to repurpose cancer drugs for Alzheimer's disease

July 27, 2016
An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals. This finding is the latest from Georgetown ...

Cancer drug prevents build-up of toxic brain protein

May 10, 2013
Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan ...

Cancer drug restores brain dopamine, reduces toxic proteins in Parkinson's, dementia

July 11, 2016
A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease ...

Cancer drug improved cognition and motor skills in small Parkinson's clinical trial

October 18, 2015
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson's disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University ...

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

Tau, not amyloid-beta, triggers neuronal death process in Alzheimer's

October 31, 2014
New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters the prevailing theory of Alzheimer's ...

Recommended for you

Investigating patterns of degeneration in Alzheimer's disease

November 17, 2017
Alzheimer's disease (AD) is known to cause memory loss and cognitive decline, but other functions of the brain can remain intact. The reasons cells in some brain regions degenerate while others are protected is largely unknown. ...

Brain activity buffers against worsening anxiety

November 17, 2017
Boosting activity in brain areas related to thinking and problem-solving may also buffer against worsening anxiety, suggests a new study by Duke University researchers.

Study may point to new treatment approach for ASD

November 17, 2017
Using sophisticated genome mining and gene manipulation techniques, researchers at Vanderbilt University Medical Center (VUMC) have solved a mystery that could lead to a new treatment approach for autism spectrum disorder ...

Neuroscience research provides evidence the brain is strobing, not constant

November 17, 2017
It's not just our eyes that play tricks on us, but our ears. That's the finding of a landmark Australian-Italian collaboration that provides new evidence that oscillations, or 'strobes', are a general feature of human perception.

Neuroscientists find chronic stress skews decisions toward higher-risk options

November 16, 2017
Making decisions is not always easy, especially when choosing between two options that have both positive and negative elements, such as deciding between a job with a high salary but long hours, and a lower-paying job that ...

Paraplegic rats walk and regain feeling after stem cell treatment

November 16, 2017
Engineered tissue containing human stem cells has allowed paraplegic rats to walk independently and regain sensory perception. The implanted rats also show some degree of healing in their spinal cords. The research, published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.